Our current study is preclinical, and we demonstrated that mTOR inhibitors showed considerable efficacy in lung cancer cells with HGF-mediated resistance to EGFR-TKI resistance both in vitro and in vivo. The gene discussed is HGF; the disease is lung carcinoma.